Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology

Advertisement

News
Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma
10/31/2023
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA...
10/31/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology

Advertisement

News
Prolonged Survival with Cancer Vaccine Among Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
10/21/2023
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial,...
10/21/2023
Oncology
News
Efficacy, Safety of Sacituzumab Govitecan Among Patients With Heavily Pretreated, Relapsed/Refractory Metastatic or Locally Advanced Head and Neck Squamous Cell Carcinoma
10/21/2023
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the...
10/21/2023
Oncology
News
No Benefit Adding Lapatinib to Chemoradiotherapy for Patients With Non-HPV Head and Neck Carcinoma
10/13/2023
In a phase 2 trial, the addition of dual EGFR-HER2 inhibitor lapatinib to chemoradiotherapy did not improve the survival outcomes among patients with non-HPV head and neck carcinoma.
In a phase 2 trial, the addition of dual EGFR-HER2 inhibitor lapatinib to chemoradiotherapy did not improve the survival outcomes among patients with non-HPV head and neck carcinoma.
In a phase 2 trial, the addition...
10/13/2023
Oncology

Advertisement

Tsz Lun Yeung, MD
Videos
Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer
07/18/2023
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting,...
07/18/2023
Oncology
News
Nivolumab Plus Ipilimumab vs Nivolumab Alone for Head and Neck Squamous Cell Carcinoma
04/27/2023
In a phase 2 trial, patients with recurrent or metastatic head and neck squamous cell carcinoma did not derive a clinical benefit from nivolumab plus ipilimumab compared to nivolumab alone.
In a phase 2 trial, patients with recurrent or metastatic head and neck squamous cell carcinoma did not derive a clinical benefit from nivolumab plus ipilimumab compared to nivolumab alone.
In a phase 2 trial, patients...
04/27/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use